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Abstract 
Intra bone marrow-bone marrow transplantation (IBM- BMT) + thymus transplantation (TT) 
has been shown to reduce the incidence of graft versus host disease (GVHD) and restore 
donor-derived T cell function. In addition, an increase in insulin sensitivity occurred in db/db 
mice after IBM-BMT+TT treatment. Heme oxygenase (HO)-1 is a stress inducible enzyme 
which exert antioxidant, antiapoptotic, and immune-modulating properties. We examined 
whether IBM-BMT+TT could modulate the expression of HO-1 in the kidneys of db/db mice. 
Six-week-old db/db mice with blood glucose levels higher than 250 mg/dl were treated with 
IBM-BMT+TT. Six weeks later, the db/db mice showed decreased body weight, blood glucose 
levels and insulin, and increased plasma adiponectin levels. The upregulation of HO-1 was 
associated with significantly (p<0.05) increased levels of peNOS and pAKT, but decreased 
levels of iNOS in the kidneys of db/db mice. Plasma creatinine levels also decreased (p<0.05), 
and the expression of type IV collagen was improved. Thus IBM-BMT+TT unregulated the 
expression of HO-1, peNOS and pAKT, while decreasing iNOS levels in the kidney of db/db 
mice. This was associated with an improvement in renal function. 
Key words: IBM-BMT+TT, antioxidant, HO-1, diabetic nephropathy. 
Introduction 
Heme oxygenase (HO)-1 is a stress inducible 
enzyme that catalyzes the degradation of heme pro-
teins into free iron, CO and biliverdin, which is then 
rapidly converted into bilirubin. These catabolic end 
products exert antioxidant, antiapoptotic, and im-
mune-modulating properties, rendering the overall 
function of HO-1 to be cytoprotective [1, 2]. Graft 
versus host disease (GVHD) is a major side effect of 
allogenic bone marrow transplantation (BMT) [3]. 
Intra bone marrow- BMT (IBM-BMT) appears to offer 
the best approach for allogenic BMT, as manifested by 
a reduced incidence of GVHD and the restoration of 
donor-derived T cell function [4-6]. We recently re-
ported that, in db/db mice treated with IBM-BMT+ 
thymus (TT) transplantation, CD4/CD8 ratios were 
normalized with a consequent increase in plasma 
adiponectin levels and insulin sensitivity. In addition, 
the expression of pancreatic phosphorylated AK 
transforming factor (pAKT), phosphorylated liver 
kinase B1 (pLKB1), phosphorylated adenosine 
monophosphate-activated protein kinase (pAMPK) 
and HO-1 increased in thus-treated db/db mice [7].  
The db/db mouse presents with renal abnor-
malities including proteinuria, glomerular hypertro-
phy, and glomerulosclerosis [8, 9], thereby making it 








vascular dysfunction in diabetic nephropathy (DN). 
DN is the major cause of end-stage renal failure, 
mainly due to the increased incidence of type 2 dia-
betes mellitus [10]. Oxidative stress (OS) is considered 
a significant pathogenic factor in the development of 
diabetic vascular complications, including nephrop-
athy [11, 12]. The beneficial effect of increased HO-1 
expression and HO activity further suggests that the 
abnormality in endothelial progenitor cells is due to a 
mesenchymal stem cell (MSC) disorder exacerbated 
by OS and decreased levels of adiponectin [13].  
In the present study, we examined whether al-
logenic IBM-BMT+TT modulated the expression of 
HO-1 in the kidneys of db/db mice and show that this 
intervention does indeed upregulate the expression of 
HO-1, phosphorylated endothelial nitric oxide syn-
thase (peNOS) and pAKT, decrease inducible NOS 
(iNOS), and improve renal function, therefore 
providing a mechanistic basis for the therapeutic use 
of IBM-BMT+TT. 
Materials and methods 
Animals  
Six-, 12- and 30-wk-old BKS.Cg-m+Leprdb/ 
+Leprdb/J (H-2Kd) (db/db) mice and age-matched 
lean mice were purchased from Charles River Labor-
atories (Yokohama, Japan) and maintained in animal 
facilities under specific pathogen-free conditions. All 
procedures were performed under protocols ap-
proved by the Institutional Animal Care and Use 
Committee at Kansai Medical University. Body 
weight and blood glucose levels were measured each 
week. Blood glucose levels higher than 250 mg/dl on 
two consecutive measurements were considered to 
indicate the onset of diabetes. Each experiment was 
repeated three times.  
IBM-BMT+TT 
Six-wk-old db/db mice with blood glucose lev-
els greater than 250 mg/dl and proteinuria greater 
than ++ on two consecutive measurements received 
fractionated irradiation twice a day (5.0 Gy×2, 4-hour 
interval). One day after irradiation, whole BMCs from 
B6 mice were injected into the recipient mice 
(1×107/mouse) by IBM-BMT using our previous-
ly-described method [7]. Simultaneously, the thymus 
from newborn B6 mice was grafted under the renal 
capsule of the left kidney of the recipient mice. All 
treated mice were sacrificed 6 wks after IBM-BMT+TT 
treatment. 
Immunochemistry and measurement of nitric 
oxide (NO) levels 
The pancreata, livers, kidneys and bones of lean 
and db mice were removed at each time point. After 
the tissues were fixed in 10% formalin for 24 hours at 
room temperature, they were embedded in paraffin. 
The sections (3-µm thick) were stained with hema-
toxylin and eosin. The pancreata were stained with 
polyclonal guinea pig anti-swine insulin antibody 
(N1542, Dako Cytomation, CA). The kidneys were 
stained with collagen type IV (Sigma-Aldrich, MO), 
pAKT, iNOS and eNOS (Abcam PLC, Cambridge, 
UK) antibodies. The stained sections were examined 
under a microscope.  
NO levels in the kidneys were measured ac-
cording to the manufacturer’s protocol using a Nitric 
Oxide Assay Kit (BioAssay Systems, Hayward, CA). 
Electron microscopy 
The fixed renal cortices were embedded in epoxy 
resin using conventional methods [14]. Kidney tissue 
was fixed in 2.5% glutaraldehyde in 0.1M PBS, pH 7.4. 
Samples were washed and post fixed with 2% aque-
ous OsO4. The samples were then dehydrated with 
serially-increasing concentrations of ethanol (60 to 
100%), and were infiltrated with epon mixed with 
methyl nadic anhydride (TAAB Laboratories, UK), 
Dodecenyl succinic anhydride (TAAB Laboratories), 
and Quetol-812 and DMP-30 (Nishin Company, Ja-
pan). Ultrathin sections were prepared, stained using 
uranyl acetate and lead citrate, and then examined 
with a JEM-1400A electron microscope (JEOL, Tokyo, 
Japan). The measurements were taken from electron 
micrographs with magnifications of x2,500 and 
x12,000. 
Adiponectin, insulin, creatinine and pancreatic 
insulin content measurements  
Adiponectin was determined in mouse plasma 
using an ELISA assay (R&D Systems, Inc. MN and 
Invitrogen Corporation CA). Insulin was measured 
using an ELISA kit (Morinaga, Yokohama, Japan).  
Plasma creatinine was measured according to 
the manufacturer’s protocols using a plasma creati-
nine detection kit (Arbor Assays, Michigan).  
 For insulin content measurement, the pancreas 
was isolated and weighed, and then placed in 3ml 
cold acid ethanol (0.18M HCl in 70% ethanol) and 
homogenated. This was kept overnight at 4°C and 
centrifuged at 2400rpm for 30min at 4°C. The super-
natant was transferred and stored at -20°C for meas-
urement using ELISA. 




Western blot analysis of kidney HO-1, peNOS, 
AKT, pAKT, and iNOS 
At sacrifice, kidneys were dissected, then pooled 
for each mouse in order to measure signaling mole-
cules. Specimens were stored at -140°C until assayed. 
Frozen kidney tissues were pulverized under liquid 
nitrogen and placed in a homogenization buffer 
(mmol/l: 10 phosphate buffer, 250 sucrose, 1 EDTA, 
0.1 PMSF and 0.1% v/v tergitol, pH 7.5). Homoge-
nates were centrifuged at 27,000 g for 10 min at 4ºC, 
and the supernatant was then isolated and protein 
levels were obtained by immunoblotting with the 
relevant antibodies. Antibodies against HO-1, AKT, 
phosphorylated AKT (pAKT), eNOS, peNOS and 
iNOS were obtained from Cell Signaling Technology, 
Inc. (Beverly, MA). Antibodies were prepared by di-
lution as described previously [15, 16]. 
Flow cytometric analyses  
Peripheral blood mononuclear cells were ob-
tained from the tail vein of mice 30 days after trans-
plantation. These cells were stained with antibodies 
against PE-H-2Kd, PE-CD4, PE-CD8a and FITC-H-2Kb 
(BD Bioscience Pharmingen, San Diego, CA) for 30 
min on ice. After washing twice with 2% FCS / PBS 
and lysing red blood cells, the 10000 events acquired 
were analyzed by FACScan (BD Bioscience). Iso-
type-matched immunoglobulins were used as con-
trols.  
Statistical analysis 
Statistical significance between experimental 
groups was determined by the Fisher method of 
analysis of multiple comparisons. For comparison 
between treatment groups, the null hypothesis was 
tested by either a single-factor ANOVA for multiple 
groups or unpaired t test for two groups. Statistical 
significance was regarded as significant at p<0.05.  
Results 
Body weight, thymus weight, and morphology 
of pancreas and bone, and insulin content of 
pancreas islet  
We first confirmed the parameters (body weight, 
thymus weight and morphology of pancreas and bone 
marrow) of the db/db mice and lean mice (as control) 
maintained in our animal facilities (Fig.1), since food 
and environment may affect some parameters of 
db/db mice. As seen in Fig. 1A, the body weight of 
12-wk-old lean mice was significantly higher than that 
of 6-wk-old lean mice (30.4 ±0.5 vs 22.6±0.1 g, p< 
0.001). Similar results occurred in the db/db mice 
(53.2 ±1.7 vs 33.5±0.03 g, p< 0.001). However, alt-
hough the body weight of 30-wk-old db/db mice was 
significantly higher than that of 12-wk-old db/db 
mice (61.2±0.6 vs 53.2± 1.7 g, p< 0.01), there was no 
significant difference in body weight between 
30-wk-old and 12-wk-old lean mice (32.4±0.5 vs 30.4± 
0.5 g). As shown in Fig. 1B, thymus weight was sig-
nificantly lower in the 6-wk-, 12-wk and 30-wk-old 
db/db mice than in the age-matched lean mice (51.7 
±4.7 vs 75.7±3.3, 21.3 ±0.9 vs 49±4.0, 20.5 ±1.2 vs 
43±4.1mg, p < 0.05 at each time point).  
On HE staining, 12-wk- and 30-wk-old db/db 
mice (Fig. 1E and F) exhibited larger islets than 6 
wk-old db/db mice and lean mice (Fig. 1C and D). 
More adipocytes were present in the bone marrow of 
12-wk- and 30-wk-old db/db mice (Fig. 1H-J) than in 
lean mice (Fig. 1G).  
The db/db mouse shows insulin resistance and 
insulin-positive cell failure. The insulin content 
(brown color) was much lower in the larger islets of 
6-wk-, 12-wk- and 30-wk-old db/db mice (Fig. 1L-N) 
than in those of lean mice (Fig. 1K), suggesting that 
more insulin was secreted into the peripheral blood in 
the db/db mice. Pancreatic insulin contents of lean 
mice (2336±84.5 pg/ml per mg pancreas), and 6-wk- 
(1149±37.5 pg/ml per pancreas), 12-wk- (521±21.7 
pg/ml per mg pancreas), and 30-wk- (180±21.3 pg/ml 
per mg pancreas) old db/db mice were measured by 
ELISA. 
Plasma creatinine levels and histology of the 
kidneys of db/db mice 
As shown in Fig. 1O, plasma creatinine levels 
were significantly higher in 12-wk-old when com-
pared to 6-wk-old db/db mice (3.41±0.20 vs 1.47±0.46 
mg/dl, p<0.05), and in 30-wk-old compared to 
12-wk-old db/db mice (4.65±0.03 vs 3.41±0.20 mg/dl, 
p<0.05). Electron microscopic images of the kidneys 
are shown in Fig. 1P-S. 12-wk and 30-wk db/db mice 
exhibited severe podocyte foot fusion. Electron dense 
deposits and increased numbers of mesangium cells 
were observed in the 30-wk-old db/db mice (Fig. 1R 
and S).  






Figure 1. Body weight, thymus weight and the morphology of pancreas and bone marrow, and expression of insulin on 
the pancreata, and plasma creatinine levels and images of electron microcopy. (A) Body weights are shown (*p< 0.01). (B) 
Thymus weights are shown (*p<0.05). (C-J) HE staining of pancreas and bone marrow of the lean and db/db mice at each age. The islets 
are shown (* in Fig.C-F). The adipocytes are shown in db/db mice (arrows in Fig. H-J). (K-N) Immunochemistry staining for insulin (arrows) 
was performed. Scale bar =50μm in Fig. C-J, Scale bar =25μm in Fig. K-N. (O) Plasma creatinine levels of lean, (p< 0.05). (P-S) EM of 
kidneys. Podocyte foot fusion is shown in Fig. 3Q and R (arrows). Electron dense deposits and increased mesangium cells (*) are shown 
in Fig. 1R and S. Scale bar =2μm in Fig. P-R, Scale bar =10μm in Fig. S. The results are mean±SE, n=6 in each group. 





Improved body weight, blood glucose and 
plasma adiponectin, and insulin levels 6 weeks 
after treatment with IBM-BMT +TT 
As seen in Fig.2A, body weight was significantly 
(p<0.01) lower in the IBM-BMT+TT treated db/db 
mice than in the age-matched non-treated db/db 
mice. In addition, fasting blood glucose levels (Fig. 
2B) were significantly (p<0.01) lower in the treated 
db/db mice than in the non-treated db/db mice. In-
deed IBM-BMT+TT reduced blood glucose to the lev-
els found in age-matched lean mice. As shown in Fig. 
2C, the non-treated db/db mice exhibited a signifi-
cantly (p<0.05) lower level of plasma adiponectin than 
age-matched lean mice. However, the plasma adi-
ponectin levels were significantly (p<0.05) increased 
in the treated db/db mice when compared to the 
non-treated db/db mice (Fig. 2C). Plasma insulin lev-
els were higher (p<0.05) in the non-treated db/db 
mice than in the age matched lean mice. 
IBM-BMT+TT treatment resulted in a decrease 
(p<0.05) in plasma insulin levels to the levels found in 
age-matched lean animals (Fig. 2D).  
Lymphocyte subpopulations in peripheral 
blood and cell number of thymus 6 weeks after 
treatment with IBM-BMT +TT 
The relative percentage of the total cell number 
in the thymus was significantly (p<0.05) lower in the 
non-treated db/db mice than in the lean mice (65.13% 
of that of lean mice). The total cell number of the 
thymus was significantly higher (p<0.05) increased in 
the treated mice (97.9% of lean mice) (Fig. 3A). Figure 
3B shows the percentages of donor-derived cells 
(H-2Kb) in the peripheral blood of the treated db/db 
mice. The percentages of donor-derived CD4+ and 
CD8+ were 10.16% and 7.81% respectively, Figure 3C 
and D.  
 
 
Figure 2. Body weight, blood glucose levels, plasma adiponectin, insulin. (A) Body weights are shown. (B) Blood glucose levels 
are shown. (C) Plasma adiponectin. (D) Plasma insulin. 
 





Figure 3. Cell number of thymus and lymphocyte subpopulations in peripheral blood. (A) The relative percentage of total cell 
numbers in the thymus, which was significantly increased in the db/db mice treated with IBM-BMT+TT. (B-D) Donor-derived cells in 
peripheral blood, CD4+ cells and CD8+ cells are shown. The results are mean±SE, n=6 in each group. 
 
Lymphocyte function 
Approximately 98% of hematolymphoid cells 
were of donor-origin in the peripheral blood of the 
recipients one month after IBM-BMT+TT treatment. 
Spleen cells of the recipient animals demonstrated 
mitogen responses to lipopolysaccharide, in contrast 
to those of non-treated db/db mice: 26296±2780.93 vs 
19292±1310.42, respectively, p<0.05. In lean mice the 
mitogen response was 31406±2780.93. These findings 
suggest that IBM-BMT+TT treatment restores lym-
phocyte function in the db/db mice. 
Expression of HO-1, iNOS, peNOS and pAKT 
in the kidney of db/db mice treated with 
IBM-BMT+TT 
The expression of renal HO-1 was significantly 
lower (p<0.05) in the non-treated db/db mice when 
compared to lean mice, but significantly increased 
(p<0.05) in db/db mice treated with IBM-BMT+TT, 
when compared with non-treated db/db mice (Fig. 
4A and B). The expression of iNOS was the receptacle 
of HO-1 expression and was significantly (p<0.05) 
higher in the non-treated db/db mice than in the lean 
mice. Densitometry analyses revealed a significant 
decrease in iNOS (p<0.05) in the kidney of treated 
db/db mice when compared with non-treated db/db 
mice (Fig. 4A and C).  
The expression of pAKT and peNOS in the kid-
ney was significantly lower (p<0.05) in the 
non-treated db/db mice when compared to the lean 
mice, but there was a significant increase in the ex-
pression of both pAKT and peNOS in the 
IBM-BMT+TT treated db/db mice, when compared 
with non-treated db/db mice (Fig. 4D-G, p<0.05). The 
expression of type IV collagen (brown color) was 
greater in the kidney of the non-treated db/db mice 
(Fig. 4I) than in the lean mice (Fig. 4H). However, it 
was significantly lower in the kidney (arrows in Fig. 
4J) in the treated db/db mice than in the non-treated 
db/db mice.  






Figure 4. Expression of HO-1, iNOS AKT, pAKT, eNOS and peNOS in the kidney, and expression of type IV collagen in 
the kidneys. (A-C) Western blot and densitometry analysis of HO-1, iNOS and actin proteins in kidneys of lean, non-treated db/db mice 
and treated db/db mice. (D and E) Western blot and densitometry analyses of AKT and pAKT and actin proteins in kidney of lean, 
non-treated db/db mice and treated db/db mice are shown. (F and G) Western blot and densitometry analyses of eNOS and peNOS and 
actin proteins in kidney of lean, non-treated db/db mice and treated db/db mice are shown. Representative immunoblots are shown. There 
were significant differences between non-treated and treated groups (p<0.05). (H-J) Immunochemistry staining for type IV collagen (*). 
(K-S) Immunochemistry staining for eNOS, pAKT and iNOS. Scale bar =25µm. (T) NO levels in the kidney. 





The expression of peNOS, pAKT and iNOS was 
confirmed by immunochemistry staining (Fig. 4K-T). 
eNOS positive cells were identified in the kidneys of 
lean, non-treated and treated db/db mice ( arrow in 
Fig. 4K-M). pAKT positive cells were identified in the 
kidney of lean and treated db/db mice (arrow in Fig. 
4N and P). However, none were found in the 
non-treated db/db mice. iNOS positive cells were 
identified in the kidney of non-treated db/db mice 
(arrow and *in Fig. 4R). 
As shown in Fig. 4T, NO levels in the kidney 
were significantly lower in non-treated db/db mice 
when compared to lean mice (0.35±0.004 vs 0.03±0.002 
µM/mg, p<0.01). However, the NO levels were sig-
nificantly higher in the kidney (0.09±0.005 vs 
0.03±0.002 µM/mg, p<0.01) in the treated db/db mice 
than in the non-treated db/db mice.  
Discussion  
Leptin receptor-deficient db/db mice exhibit 
severe hereditary obesity [17] and display hormonal 
imbalances and hematolymphoid defects [18, 19]. 
db/db mice exhibit a marked reduction in the size 
and cellularity of the thymus [20, 21]. Thus we firstly 
confirmed the body weight and thymus weight of 
db/db and lean mice at each age that were main-
tained in our animal facilities. Meantime, the mor-
phology of the pancreas, kidney and bone marrow 
was also confirmed (Figure 1- 3). There were signifi-
cant differences in body weight and thymus weight 
between 6-wk-and 12-wk-old mice. The pancreas, 
kidney and bone marrow showed differences in 
morphology at each time point. Previous studies have 
shown that IBM-BMT+TT improved insulin sensitiv-
ity in db/db mice 7 wks after treatment [7]. However, 
there are no reports indicating whether IBM-BMT+TT 
increased HO-1 expression, or benefited the kidney in 
db/db mice, although a protective effect of BMT on 
renal pathology has been reported [22]. 
HO-1 is the inducible form of HO (HO-2 is the 
constitute form) and is increased in response to OS. 
Increased levels of HO-1 slow the rate of weight gain 
and decrease levels of TNF-α and IL-6, but increase 
serum levels of adiponectin in obese diabetic mice 
[15]. db/db mice treated with IBM-BMT+TT exhibited 
a larger decrease in body weight and plasma insulin 
levels than age-matched non-treated db/db mice. 
Insulin administration to treated db/db mice pro-
duced a rapid decrease in blood glucose levels, sug-
gesting improved insulin sensitivity after 
IBM-BMT+TT treatment. In the present study, HO-1 
expression increased in the kidney after IBM-BMT+TT 
and was accompanied by an enhanced expression of 
peNOS and pAKT. A reduction in the production of 
nitric oxide [23] and a decrease in the expression of 
eNOS are reportedly associated with advanced DN 
[24]. An increase in AKT signaling is considered an 
important metabolic response to OS through the at-
tenuation of ROS-mediated endothelial dysfunction 
[25]. The up regulation of renal HO-1 expression with 
a resultant increase in signaling molecules, including 
adiponectin via the pAKT-pAMPK-peNOS pathway, 
prevents the development of metabolic syndrome and 
improves both vascular and renal function [26].  
HO has been shown to be important for attenu-
ating the overall production of reactive oxygen spe-
cies (ROS) through its ability to degrade heme and to 
produce carbon monoxide (CO), biliverdin/bilirubin, 
and the release of free iron, which possess potent an-
tioxidant properties and antiapoptotic effects [26]. 
Recently, the induction of HO-1 has been found to 
reduce diabetic induced-glomerular injury and 
apoptosis, and these effects are associated with de-
creased NF-κB-induced inflammation and oxidative 
stress [27]. MSCs have the capacity to repair renal 
injury, accelerate tubular proliferation and improve 
renal function, and upregulate HO-1 expression and 
increase HO activity, all are essential for MSC growth 
and differentiation to the osteoblast lineage, which is 
consistent with the role of HO-1 in hematopoietic 
stem cell differentiation [28]. Induction of HO-1 by 
cobalt-protoporphyrin IX in recipient mice before 
conditioning and bone marrow transplantation (BMT) 
results in a reduction of GVHD and improved sur-
vival [29]. One report has indicated that HO-1 in 
dendritic cells may function as an inhibitor of the al-
loimmune response mediated by CD4+ T cells. HO-1 
could thus play a key role in the design of therapies to 
prolong allograft function, based on the potent allo-
immunity modulating capacity of this enzyme [30].  
Plasma adiponectin levels are also significantly 
higher in treated db/db mice than in non-treated 
db/db mice. Adiponectin is a key regulator of albu-
minuria, suppressing not only i) OS and albuminuria 
but also ii) high levels of adiponectin phosphorylase 
and iii) active AMPK, presumably via adipoR1, which 
prevents OS and the fusion of the podocyte foot pro-
cesses [31]. There is a report supporting the hypothe-
sis that adiponectin is critical for both endothelial cell 
survival and function via the activation of eNOS and 
crosstalk between pAKT and pAMPK [32].  
Bone marrow cells have the capacity to differen-
tiate into mesangial cells [33, 34] and to transdifferen-
tiate into podocytes. This is accompanied by the 
re-expression of the defective collagen chains and 
improved renal histology and function [35]. MSCs 
have the capacity to repair renal injury, accelerate 
tubular proliferation and improve renal function [36, 




37]. Nephrons are of mesenchymal origin and stroma 
cells are of crucial importance for signaling, leading to 
the differentiation of both nephrons and collecting 
ducts [38]. Bone marrow-derived mesangial cell pro-
genitors may play a crucial role in the development 
and progression of extracellular matrix accumulation 
and mesangial cell proliferation in the db/db mouse. 
Future studies to clarify extra-cellular matrix accu-
mulation will focus on the donor-derived BM cells in 
the kidneys of the recipient.  
Type IV collagen is a major structural compo-
nent of all basement membranes, including the glo-
merular basement membrane of the kidney in verte-
brates and invertebrates [39, 40]. Our results show 
that the expression of type IV collagen in the glomer-
ulus was attenuated after IBM-BMT+TT. BM-derived 
cells fuse with existing glomerular cells and thereby 
provide therapeutic benefit or, alternatively, transfer 
their nuclei to damaged podocytes and thereby enable 
repair. Bone marrow-derived stem cells repair base-
ment membrane collagen defects and reverse genetic 
kidney disease [35].  
Age-related hematologic changes are associated 
with a decline in BM cellularity and a decline in 
adaptive immunity [41, 42]. The thymus involutes 
steadily with increasing age, resulting in a decreased 
release of new naïve T cells to the periphery, thereby 
affecting adaptive immunity [43]. The thymus also 
undergoes age-related progressive involution with 
decreased thymic lymphopoiesis, reduced thymic size 
and disrupted thymic architecture. Our previous 
studies demonstrated that the thymus is significantly 
lighter in db/db mice than in age-matched lean mice. 
When thymi from newborn C57BL6 mice were trans-
planted into db/db mice, the percentage of dou-
ble-positive, double-negative and CD4+ cells in the 
thymus was normalized, as was the CD4/CD8 ratio in 
the peripheral blood [7], and the total cell number of 
the thymus, suggesting that IBM-BMT+TT is capable 
of restoring the immune repertoire and overcoming 
the autoimmune response, which is considered to be 
partly responsible for the development of diabetes. 
IBM-BMT appears to be the most appropriate 
strategy for allogenic BMT [4]. Moreover, allogenic 
IBM-BMT+TT normalizes T cell subsets, cytokine 
imbalance and insulin sensitivity in db/db mice [7]. 
Allogenic IBM-BMT+TT upregulates the expression of 
HO-1 in kidney. This is followed by the upregulation 
of peNOS and pAKT and a reduction in iNOS levels, 
resulting in an improvement in renal function. This 
therapeutic approach offers decided advantages in the 
treatment of both autoimmune and hematological 
diseases. 
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